Dimerix Ltd has released a press release.
Investor Update
Filed with ASX ·
On 6ix: 6ix.com/news/investor-update-39
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Receipt of $420k Research & Development Tax Refund
- Corporate Presentation
- Key Patent Allowed in Japan
- Dimerix Raises $2 million to Advance Clinical Program
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
Later from Dimerix
- Research Validates Relevance of DMX Receptor-HIT Technology
- Positive Results from Phase 2a Trial of DMX-200
- DMX-200 tablet manufacture and human study timeline
- Notice of Annual General Meeting/Proxy Form
- Dimerix Receives $545k R&D Tax Refund
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix